FT576 vs HRC0202

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

FT576

Developed by Fate Therapeutics

Phase 1 in Multiple Myelomacell therapy (allogeneic iPSC-derived CAR-NK)
Weak signal

NCT05182073 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Incidence and nature of DLTs within each dose-escalation cohort to determine the MTD or MAD (Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1); Determine the RP2D which will be based on the overall safety and anti-tumor activity among the dose escalation and dose expansion cohorts (From FPI to LPI's end of Cycle 1 study treatment (End of cycle is Day 29 from Day 1 FT576 infusion)); Incidence, nature, and severity of adverse events (Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1): 12 patients were treated with a three-dose treatment schedule at 1 billion cells per dose (n=6) or 2.5 billion cells per dose (n=6). There were no dose-limiting toxicities and no events of any grade of CRS, ICANS or GvHD. Five of six (83%) heavily pre-treated patients achieved a clinical response at 1 billion cells per dose, including two penta-exposed patients treated with FT576 as monotherapy who achieved very good partial responses.

Result source: NCT05182073

HRC0202

Developed by Hrain Biotechnology Co., Ltd.

Phase 2 in Multiple MyelomaCAR-T (autologous, BCMA-directed)
Weak signal

NCT04003168 · Phase 1 · status unknown

This is a small, single-arm, open-label safety study with no control group, so it cannot show whether the therapy works better than an alternative. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

The published report covers seven treated patients, fewer than the study's listed enrollment.

Reported efficacy

Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0 (28 days post infusion): In seven patients with relapsed/refractory multiple myeloma previously treated with anti-BCMA CAR-T (four relapsed, three refractory), the best overall response rate was 71.4% (5/7), with stringent complete response or complete response achieved in three patients. Cytokine release syndrome of grades 1-2 occurred in three patients (42.9%) and grade >=3 in two patients (28.6%).

Result source: NCT04003168

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFT576HRC0202
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
VGPR or better—Not reported—Not reported
MRD negativity—Not reported—Not reported

PFS, median

FT576
—Not reported
HRC0202
—Not reported

OS, median

FT576
—Not reported
HRC0202
—Not reported

ORR

FT576
—Not reported
HRC0202
—Not reported

VGPR or better

FT576
—Not reported
HRC0202
—Not reported

MRD negativity

FT576
—Not reported
HRC0202
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

FT576: no structured comparison results are available for Multiple Myeloma.

HRC0202: no structured comparison results are available for Multiple Myeloma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: FT576's landscape · HRC0202's landscape